Weight-loss medications reduced body weight in children and teens, but the sample size was too small to make conclusions ...

Real-world data showed high incidence of hair loss among GLP-1 receptor agonist users, but the phenomenon is probably an ...

NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for ...

Oral semaglutide (Rybelsus®) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular ...

Researchers have found bariatric surgery to be more cost-effective for treating patients with obesity compared with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to new study ...

Researchers in Denmark observed a significant drop-off in anti-obesity drug usage after 1 year in first-time users.

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with ...

Novo Nordisk's Rybelsus gains EU approval for cardiovascular benefits, enhancing treatment options for type 2 diabetes and ...

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk ...

Patients who received zovaglutide at a once-monthly dose of 160 mg experienced a 13.8% reduction in body weight at 24 weeks, highly comparable to reductions observed in patients who received 80 mg ...

Results show that GLP-1s may address rheumatoid arthritis (RA) symptoms, independent of established weight loss and cardiac benefits, by reducing the systemic, chronic inflammation associated with RA.